Compared to control cells, MSLN-deficient HCC1806/HM3 cells showed significantly reduced IC50 values for Paclitaxel and Carboplatin (Fig. 8A), as well as decreased tumor cell viability (Fig. 8B), suggesting that combining MSLN deficiency with Paclitaxel and Carboplatin could be effective in TNBC liver metastases. The gene discussed is MSLN; the disease is neoplasm.